RxDoctor Payments DataLook up a doctor →

Francisco Perez, MD

Clinical Cardiac Electrophysiology · Ponce, PRNPI 1851359384

Payments from drug & device makers

$285,694in general payments, 2019–2025

Across 1,211 payments — averaging $235.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$147K
  • Abbott$82K
  • Boston Scientific$22K
  • Novartis$18K
  • Medtronic$14K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$710
  • plus $2K from 15 others
$75,139in research payments, 2019–2025

Across 44 payments — averaging $1707.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$75K
  • Boston Scientific$614

What the payments were for

  • Consulting fees$7,6884%
  • Speaking & faculty fees$158,21078%
  • Travel & lodging$12,0506%
  • Food & beverage$23,66312%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$285,694 in reported general payments places this provider in the 95th percentile of 22 clinical cardiac electrophysiology providers in Puerto Rico.

See all clinical cardiac electrophysiology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$29,791
Medicare patients
55
Services billed
167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$102,464
XareltoRivaroxaban98$65,753
Flecainide Acetate146$6,143
Metoprolol Succinate164$1,882
Amiodarone Hcl102$1,819
Cephalexin90$825
Fludrocortisone Acetate16$570
Carvedilol74$451
Losartan Potassium45$362
Digoxin24$359
Nifedipine ErNifedipine12$317
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide17$307
Furosemide44$254
Metolazone24$254
Bumetanide18$246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$146,983$65,75398 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 clinical cardiac electrophysiology providers in Puerto Rico.

Other clinical cardiac electrophysiology in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →